🔎 Trials Near Me

Akèy › Sipwa › Tennessee › Knoxville

Etid klinik pou Sipwa nan Knoxville, TN

7 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Knoxville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Ap rekriteFaz 3
  • New Phase Research and Development, Knoxville
  • Accellacare US Inc., d/b/a Accellacare of Knoxville, Knoxville
Laj 18 a 99 · Tout sèks · Mizajou Oct 5, 2026 · NCT07684235

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Ap rekriteFaz 3
  • Accellacare of Knoxville, Knoxville
  • Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell · 8 mi lwen
Laj 45 a 99 · Tout sèks · Mizajou Oct 5, 2026 · NCT07037433

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Ap rekriteFaz 2
  • New Phase Research & Development /ID# 282131, Knoxville
  • Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07752979

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Ap rekriteFaz 3
  • New Phase Research and Development, Knoxville
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Ap rekriteFaz 3
  • Research Site, Knoxville
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Ap rekriteFaz 3
  • ACCOMPLISH-1 Research Site, Knoxville
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Ap rekriteFaz 1
  • MBX Biosciences Investigational Site, Knoxville
Laj 18 a 65 · Tout sèks · Mizajou Jun 9, 2026 · NCT07142707

Etid Sipwa nan lòt vil

Lòt etid nan Knoxville

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.